Fast Induced Remodeling in Heart Failure With Preserved Ejection Fraction
FIRE-HFpEF is a multi-center, prospective, randomized, single-blinded, clinical feasibility study. This study will enroll up to 105 subjects with heart failure with preserved ejection fraction in the United States. Data will be collected to evaluate whether pacing therapies can lead to improvements in exercise capacity and health status of subjects.
• Diagnosis of Heart Failure, Left Ventricular Ejection Fraction (LVEF) ≥ 55% (this and other measurements must be made within the last year).
• New York Heart Association (NYHA) Functional Class I-III
• Stable on guideline-directed medical therapy (GDMT) heart failure medications as determined by the investigator, for at least 1 month, with the exception of loop diuretic therapy. GDMT should be in accordance with current American Heart Association (AHA)/American College of Cardiology (ACC)/Heart Failure Society of America (HFSA) Guidelines and include consideration of Sodium/glucose cotransporter-2 inhibitors (SGLT2i) therapy.
• V End Diastolic Volume indexed to body surface area (BSA) ≤ 80 mL/m\^2.
• Concentric remodeling or concentric hypertrophy defined as at least one of the following criteria:
‣ Left ventricular (LV) posterior or lateral wall thickness \> 11mm
⁃ Relative wall thickness (RWT) \> 0.42
⁃ Male and LV mass indexed to BSA ≥115 g/m2
⁃ Male and LV mass indexed to height ≥ 49.2 g/m2.7
⁃ Female and LV mass indexed to BSA ≥ 95 g/m2
⁃ Female and LV mass indexed to height ≥ 46.7 g/m2.7